Status Epilepticus and Beyond: A Clinical Review of Status Epilepticus and an Update on Current Management Strategies in Super-refractory Status Epilepticus

키워드

참고문헌 (115)

1. Dham BS, "The epidemiology of status epilepticus in the United States", Neurocrit Care, 20, pp.476~483 (2014)
2. Penberthy LT, "Estimating the economic burden of status epilepticus to the health care system", Seizure, 14, pp.46~51 (2005)
3. Strzelczyk A, "Inpatient treatment costs of status epilepticus in adults in Germany", Seizure, 22, pp.882~885 (2013)
4. Gastaut H., "Clinical and electroencephalographical classification of epileptic seizures", Epilepsia, 11, pp.102~113 (1970)
5. Brodie MJ., "Status epilepticus in adults", Lancet, 336, pp.551~552 (1990)
6. Meldrum BS, "Physiology of status epilepticus in primates", Arch Neurol, 28, pp.1~9 (1973)
7. Trinka E, "A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus", Epilepsia, 56, pp.1515~1523 (2015)
8. Lowenstein DH, "Status epilepticus", N Engl J Med, 338, pp.970~976 (1998)
9. Brophy GM, "Guidelines for the evaluation and management of status epilepticus", Neurocrit Care, 17, pp.3~23 (2012)
10. Mayer SA, "Refractory status epilepticus:frequency, risk factors, and impact on outcome", Arch Neurol, 59, pp.205~210 (2002)
11. Holtkamp M, "Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit", J Neurol Neurosurg Psychiatry, 76, pp.534~539 (2005)
12. Ferlisi M, "The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy", Brain, 135(Pt 8), pp.2314~2328 (2012)
13. Beg JM, "Burden of illness for super-refractory status epilepticus patients", J Med Econ, 20, pp.45~53 (2017)
14. Gaspard N, "New-onset refractory status epilepticus: etiology, clinical features, and outcome", Neurology, 85, pp.1604~1613 (2015)
15. DeLorenzo RJ, "Epidemiology of status epilepticus", J Clin Neurophysiol, 12, pp.316~325 (1995)
16. DeLorenzo RJ, "Status epilepticus in children, adults, and the elderly", Epilepsia, 33(Suppl 4), pp.S15~S25 (1992)
17. Shinnar S, "In whom does status epilepticus occur: age-related differences in children", Epilepsia, 38, pp.907~914 (1997)
18. Glaser CA, "Refractory status epilepticus in suspect encephalitis", Neurocrit Care, 9, pp.74~82 (2008)
19. Van Lierde I, "De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: a review of six cases", Acta Neurol Belg, 103, pp.88~94 (2003)
20. Wilder-Smith EP, "The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity", Ann Acad Med Singapore, 34, pp.417~420 (2005)
21. Hoerth MT, "Malignant status epilepticus syndrome: refractory idiopathic status epilepticus", Epilepsia, 48, pp.P012~ (2007)
22. Costello DJ, "Cryptogenic New Onset Refractory Status Epilepticus (NORSE) in adults: infectious or not?", J Neurol Sci, 277, pp.26~31 (2009)
23. Holmes GL, "Seizing hold of seizures", Nat Med, 9, pp.994~996 (2003)
24. Chen JW, "Advances in the pathophysiology of status epilepticus", Acta Neurol Scand, 115(4 Suppl), pp.7~15 (2007)
25. Mazarati AM, "Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus", Brain Res, 814, pp.179~185 (1998)
26. Theodore WH, "The secondarily generalized tonic-clonic seizure: a videotape analysis", Neurology, 44, pp.1403~1407 (1994)
27. Mazarati AM, "Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus", J Neurosci, 18, pp.10070~10077 (1998)
28. Mazarati A, "Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus", Neuroscience, 89, pp.167~173 (1999)
29. Liu H, "Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus", Proc Natl Acad Sci U S A, 96, pp.5286~5291 (1999)
30. Vezzani A, "Neuropeptide Y:emerging evidence for a functional role in seizure modulation", Trends Neurosci, 22, pp.25~30 (1999)
31. Meldrum BS, "Systemic factors and epileptic brain damage: prolonged seizures in paralyzed, artificially ventilated baboons", Arch Neurol, 29, pp.82~87 (1973)
32. Meldrum BS, "Prolonged epileptic seizures in primates: ischemic cell change and its relation to ictal physiological events", Arch Neurol, 28, pp.10~17 (1973)
33. Nevander G, "Status epilepticus in well-oxygenated rats causes neuronal necrosis", Ann Neurol, 18, pp.281~290 (1985)
34. Wasterlain CG, "Pathophysiological mechanisms of brain damage from status epilepticus", Epilepsia, 34(Suppl 1), pp.S37~S53 (1993)
35. Pollard H, "Kainateinduced apoptotic cell death in hippocampal neurons", Neuroscience, 63, pp.7~18 (1994)
36. Niquet J, "Hypoxic neuronal necrosis: protein synthesis-independent activation of a cell death program", Proc Natl Acad Sci U S A, 100, pp.2825~2830 (2003)
37. DeGiorgio CM, "Serum neuron-specific enolase in human status epilepticus", Neurology, 45, pp.1134~1137 (1995)
38. DeGiorgio CM, "Serum neuron-specific enolase in the major subtypes of status epilepticus", Neurology, 52, pp.746~749 (1999)
39. Corsellis JA, "Neuropathology of status epilepticus in humans", Adv Neurol, 34, pp.129~139 (1983)
40. Engel J Jr, "Prolonged partial complex status epilepticus: EEG and behavioral observations", Neurology, 28(9 Pt 1), pp.863~869 (1978)
41. DeGiorgio CM, "Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus", Epilepsia, 37, pp.606~609 (1996)
42. Rabinowicz AL, "Neuron-specific enolase is increased after nonconvulsive status epilepticus", Epilepsia, 36, pp.475~479 (1995)
43. Shirasaka Y., "Lack of neuronal damage in atypical absence status epilepticus", Epilepsia, 43, pp.1498~1501 (2002)
44. Cockerell OC, "Complex partial status epilepticus: a recurrent problem", J Neurol Neurosurg Psychiatry, 57, pp.835~837 (1994)
45. Cherian A, "Status epilepticus", Ann Indian Acad Neurol, 12, pp.140~153 (2009)
46. Lothman E., "The biochemical basis and pathophysiology of status epilepticus", Neurology, 40(5 Suppl 2), pp.13~23 (1990)
47. Claassen J, "Detection of electrographic seizures with continuous EEG monitoring in critically ill patients", Neurology, 62, pp.1743~1748 (2004)
48. Schmitt SE., "Utility of clinical features for the diagnosis of seizures in the intensive care unit", J Clin Neurophysiol, 34, pp.158~161 (2017)
49. Bleck TP., "Status epilepticus and the use of continuous EEG monitoring in the intensive care unit", Continuum (Minneap Minn), 18, pp.560~578 (2012)
50. Wittman JJ Jr, "Continuous electroencephalogram monitoring in the critically ill", Neurocrit Care, 2, pp.330~341 (2005)
51. Friedman D, "Continuous electroencephalogram monitoring in the intensive care unit", Anesth Analg, 109, pp.506~523 (2009)
52. Laccheo I, "Non-convulsive status epilepticus and non-convulsive seizures in neurological ICU patients", Neurocrit Care, 22, pp.202~211 (2015)
53. Towne AR, "Prevalence of nonconvulsive status epilepticus in comatose patients", Neurology, 54, pp.340~345 (2000)
54. Westover MB, "The probability of seizures during EEG monitoring in critically ill adults", Clin Neurophysiol, 126, pp.463~471 (2015)
55. Swisher CB, "Baseline EEG pattern on continuous ICU EEG monitoring and incidence of seizures", J Clin Neurophysiol, 32, pp.147~151 (2015)
56. Shafi MM, "Absence of early epileptiform abnormalities predicts lack of seizures on continuous EEG", Neurology, 79, pp.1796~1801 (2012)
57. Glauser T, "Evidence-based guideline:treatment of convulsive status epilepticus in children and adults. Report of the Guideline Committee of the American Epilepsy Society", Epilepsy Curr, 16, pp.48~61 (2016)
58. Treiman DM, "A comparison of four treatments for generalized convulsive status epilepticus:Veterans Affairs Status Epilepticus Cooperative Study Group", N Engl J Med, 339, pp.792~798 (1998)
59. Trinka E, "Pharmacotherapy for status epilepticus", Drugs, 75, pp.1499~1521 (2015)
60. Cranford RE, "Intravenous phenytoin in acute treatment of seizures", Neurology, 29, pp.1474~1479 (1979)
61. Patsalos PN., "Clinical pharmacokinetics of levetiracetam", Clin Pharmacokinet, 43, pp.707~724 (2004)
62. Misra UK, "Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study", J Neurol, 259, pp.645~648 (2012)
63. Yasiry Z, "The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepineresistant convulsive status epilepticus: a meta-analysis of published studies", Seizure, 23, pp.167~174 (2014)
64. Claassen J, "Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review", Epilepsia, 43, pp.146~153 (2002)
65. Singhi S, "Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus", J Child Neurol, 17, pp.106~110 (2002)
66. Kumar A, "Intravenous midazolam for the treatment of refractory status epilepticus", Crit Care Med, 20, pp.483~488 (1992)
67. Stover JF, "Barbiturate coma may promote reversible bone marrow suppression in patients with severe isolated traumatic brain injury", Eur J Clin Pharmacol, 54, pp.529~534 (1998)
68. Melamed R, "Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol:mediating mechanisms and prophylactic measures", Anesth Analg, 97, pp.1331~1339 (2003)
69. Krishnamurthy KB, "Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus", Epilepsia, 40, pp.759~762 (1999)
70. Rossetti AO, "Refractory status epilepticus: effect of treatment aggressiveness on prognosis", Arch Neurol, 62, pp.1698~1702 (2005)
71. Bourgeois BF., "Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed?", Neurology, 55(11 Suppl 3), pp.S11~S16 (2000)
72. Ramael S, "Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects", Clin Ther, 28, pp.734~744 (2006)
73. Smith BS, "Introduction to drug pharmacokinetics in the critically ill patient", Chest, 141, pp.1327~1336 (2012)
74. Swadron SP, "A comparison of phenytoin-loading techniques in the emergency department", Acad Emerg Med, 11, pp.244~252 (2004)
75. May T, "Serum concentrations of valproic acid: influence of dose and comedication", Ther Drug Monit, 7, pp.387~390 (1985)
76. Perucca E., "Clinically relevant drug interactions with antiepileptic drugs", Br J Clin Pharmacol, 61, pp.246~255 (2006)
77. Wasterlain CG, "Rational polytherapy in the treatment of acute seizures and status epilepticus", Epilepsia, 52(Suppl 8), pp.70~71 (2011)
78. Abend NS, "Treatment of refractory status epilepticus: literature review and a proposed protocol", Pediatr Neurol, 38, pp.377~390 (2008)
79. Lee JW, "Rational polytherapy with antiepileptic drugs", Pharmaceuticals (Basel), 3, pp.2362~2379 (2010)
80. Gillard M, "Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain:relationship to anti-convulsant properties", Eur J Pharmacol, 664, pp.36~44 (2011)
81. Nicolas JM, "Brivaracetam, a selective highaffinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action", Epilepsia, 57, pp.201~209 (2016)
82. Wasterlain C, "Brivaracetam is a potent anticonvulsant in experimental status epilepticus", Epilepsia, 46(suppl 8), pp.219~220 (2005)
83. Rogawski MA, "Neuroactive steroids for the treatment of status epilepticus", Epilepsia, 54(Suppl 6), pp.93~98 (2013)
84. Vaitkevicius H, "Successful allopregnanolone treatment of new onset refractory status epilepticus (NORSE) syndrome: first in man experience", Epilepsia, 54(suppl 6), pp.106~124 (2013)
85. Broomall E, "Pediatric super-refractory status epilepticus treated with allopregnanolone", Ann Neurol, 76, pp.911~915 (2014)
86. "A study with SAGE-547 for super-refractory status epilepticus" (2000)[URL]
87. White HS, "A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage", Epilepsia, 53, pp.134~146 (2012)
88. Bar-Klein G, "sec-Butylpropylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats", Epilepsia, 55, pp.1953~1958 (2014)
89. Novak GP, "Carisbamate (RWJ-333369)", Neurotherapeutics, 4, pp.106~109 (2007)
90. Francois J, "A new drug RWJ 333369 protects limbic areas in the lithium-pilocarpine model (li-pilo) of epilepsy and delays or prevents the occurrence of spontaneous seizures", Epilepsia, 46(suppl 8), pp.269~270 (2005)
91. Synowiec AS, "Ketamine use in the treatment of refractory status epilepticus", Epilepsy Res, 105, pp.183~188 (2013)
92. Gaspard N, "Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study", Epilepsia, 54, pp.1498~1503 (2013)
93. Kramer AH., "Early ketamine to treat refractory status epilepticus", Neurocrit Care, 16, pp.299~305 (2012)
94. Kofke WA, "Isoflurane for refractory status epilepticus: a clinical series", Anesthesiology, 71, pp.653~659 (1989)
95. Mirsattari SM, "Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane", Arch Neurol, 61, pp.1254~1259 (2004)
96. Zhumadilov A, "Management of super-refractory status epilepticus with isoflurane and hypothermia", Front Neurol, 5, pp.286~ (2015)
97. Varvel NH, "Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus", Proc Natl Acad Sci U S A, 113, pp.E5665~E5674 (2016)
98. Alyu F, "Inflammatory aspects of epileptogenesis:contribution of molecular inflammatory mechanisms", Acta Neuropsychiatr, 29, pp.1~16 (2017)
99. Shorvon S, "The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol", Brain, 134(Pt 10), pp.2802~2818 (2011)
100. Thakur KT, "Ketogenic diet for adults in super-refractory status epilepticus", Neurology, 82, pp.665~670 (2014)
101. Fang Ye, "Efficacy of and Patient Compliance with a Ketogenic Diet in Adults with Intractable Epilepsy: A Meta-Analysis", Journal of Clinical Neurology, 11(1), pp.26~31 (2015), 대한신경과학회[DOI]
102. Liu Z, "Effect of temperature on kainic acid-induced seizures", Brain Res, 631, pp.51~58 (1993)
103. Lundgren J, "Hyperthermia aggravates and hypothermia ameliorates epileptic brain damage", Exp Brain Res, 99, pp.43~55 (1994)
104. Corry JJ, "Hypothermia for refractory status epilepticus", Neurocrit Care, 9, pp.189~197 (2008)
105. Legriel S, "Hypothermia for neuroprotection in convulsive status epilepticus", N Engl J Med, 375, pp.2457~2467 (2016)
106. Zeiler FA, "Electroconvulsive therapy for refractory status epilepticus: a systematic review", Seizure, 35, pp.23~32 (2016)
107. Lhatoo SD, "The surgical treatment of status epilepticus", Epilepsia, 48(Suppl 8), pp.61~65 (2007)
108. Mendes A, "Brain magnetic resonance in status epilepticus: a focused review", Seizure, 38, pp.63~67 (2016)
109. MD’Giano CH, "Treatment of refractory partial status epilepticus with multiple subpial transection: case report", Seizure, 10, pp.382~385 (2001)
110. Ma X, "Neurosurgical treatment of medically intractable status epilepticus", Epilepsy Res, 46, pp.33~38 (2001)
111. Ng YT, "Neurosurgical treatment of status epilepticus", J Neurosurg, 105(5Suppl), pp.378~381 (2006)
112. Dillien P, "New-onset refractory status epilepticus: more investigations, more questions", Case Rep Neurol, 8, pp.127~133 (2016)
113. Zeiler FA, "VNS for refractory status epilepticus", Epilepsy Res, 112, pp.100~113 (2015)
114. Neligan A, "Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review", Arch Neurol, 67, pp.931~940 (2010)
115. Sutter R, "Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study", Neurology, 82, pp.656~664 (2014)

관련 논문AI추천